Research programme: gastric acid pump antagonists - RaQualia Pharma

Drug Profile

Research programme: gastric acid pump antagonists - RaQualia Pharma

Alternative Names: RQ-00000774

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma
  • Class
  • Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gastro-oesophageal-reflux in Japan (PO)
  • 25 Jun 2015 RaQualia receives patent allowance for gastric acid pump antagonists in Japan
  • 20 Nov 2012 Preclinical development is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top